Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress

World News: . []

In the panel sessions, Dr David Roblin, Chief Operating Officer and President of R&D, Dr Richard Vickers, Chief Scientific Officer, and Dr David Powell, Head of Research, will highlight the potential benefits of developing new mechanistic classes of precision antibiotics, including potency against resistant and non-resistant bacteria with minimal disturbance to the gut microbiome. This supports the principles of antibiotic stewardship.

Details of the sessions:7 November 2019 2:10pm EST Roundtable 3 Innovation & Stewardship – Advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship


More news and information about Summit Therapeutics plc

Published By:

Globe Newswire: 12:00 GMT Wednesday 6th November 2019

Published: .

Search for other references to "summit" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us